Last updated: August 1, 2026
CERETEC is a radiopharmaceutical kit containing exametazime, also known as HMPAO, for preparation with technetium Tc-99m. Its primary clinical uses are cerebral perfusion imaging and in vitro labeling of leukocytes for scintigraphic localization of infection or inflammation. CERETEC is a mature diagnostic product with no meaningful new-drug clinical development program, limited patent protection, and demand tied to nuclear-medicine infrastructure rather than prescription-drug adoption.
The commercial outlook is stable to modestly declining in developed markets, with growth concentrated in hospital imaging, infection workups, dementia-related brain perfusion imaging, and regions expanding access to SPECT services.
What is CERETEC used for?
CERETEC is used to prepare technetium Tc-99m exametazime injection. The product is supplied as a nonradioactive kit; the radioactive dose is produced by reconstituting the kit with sodium pertechnetate Tc-99m.
| Attribute |
CERETEC |
| Active diagnostic agent |
Technetium Tc-99m exametazime |
| Nonradioactive precursor |
Exametazime, also called HMPAO |
| Dosage form |
Radiopharmaceutical kit |
| Main imaging modality |
SPECT and planar scintigraphy |
| Main indications |
Cerebral perfusion imaging; leukocyte labeling |
| Common clinical applications |
Stroke assessment, dementia evaluation, seizure-related perfusion studies, infection and inflammation localization |
| U.S. regulatory holder historically associated with product |
GE Healthcare |
| FDA regulatory pathway |
Approved radiopharmaceutical NDA |
| U.S. NDA |
NDA 019793 |
| Patent position |
Core composition and original-use patents are expired or commercially immaterial |
| Biosimilar relevance |
None; CERETEC is a small-molecule radiopharmaceutical, not a biologic |
The product label describes cerebral perfusion imaging and in vitro leukocyte labeling as separate uses. Leukocyte labeling requires collection of a patient’s white blood cells, incubation with the radiolabeled compound, washing, and reinjection before imaging. [1]
What is the current CERETEC clinical-trial status?
CERETEC has no conventional late-stage clinical-trial program. The product has been marketed for decades, and its regulatory value comes from established diagnostic performance rather than from new efficacy trials.
Clinical evidence supporting CERETEC
The clinical evidence base consists primarily of:
- Earlier controlled or comparative studies supporting cerebral perfusion imaging.
- Studies comparing Tc-99m exametazime-labeled leukocytes with other infection-imaging approaches.
- Diagnostic accuracy studies in osteomyelitis, inflammatory bowel disease, prosthetic joint infection, fever of unknown origin, and other suspected infection settings.
- Research protocols using cerebral perfusion SPECT in dementia, epilepsy, cerebrovascular disease, and neuropsychiatric disorders.
- Technical studies addressing radiolabeling efficiency, image quality, cell viability, and kit preparation.
These studies generally evaluate the imaging procedure rather than seek a new indication for CERETEC itself. The relevant clinical endpoint is diagnostic localization or perfusion-pattern characterization, not therapeutic benefit.
Does CERETEC have active ClinicalTrials.gov development?
CERETEC is not positioned as an active pipeline asset in the manner of a new molecular entity, oncology agent, or biologic. Current research involving exametazime or Tc-99m-labeled leukocytes is generally investigator-led and protocol-specific. It does not create a conventional exclusivity period or materially extend the product’s market protection.
The most commercially relevant continuing evidence areas are:
- Infection and inflammation imaging using autologous leukocytes.
- Cerebral perfusion SPECT in dementia and neurodegenerative disease.
- Epilepsy localization and presurgical evaluation.
- Comparison with fluorodeoxyglucose PET, amyloid PET, white blood cell scintigraphy, and newer infection-imaging agents.
- Standardization of automated or semi-automated cell-labeling workflows.
What is the FDA status of CERETEC?
CERETEC is an FDA-approved radiopharmaceutical kit. The product is regulated as a diagnostic radiopharmaceutical rather than as a therapeutic drug. Its practical regulatory requirements include control of radiochemical purity, sterility, kit stability, labeling instructions, dose preparation, and handling of radioactive material.
FDA regulatory milestones
| Milestone |
Status |
| Original U.S. approval |
Historical approval under NDA 019793 |
| Product category |
Diagnostic radiopharmaceutical kit |
| Approval type |
Full NDA approval |
| New molecular entity exclusivity |
Expired |
| Pediatric exclusivity |
Not a current commercial protection |
| Orphan-drug exclusivity |
Not a material CERETEC protection |
| Current regulatory focus |
Manufacturing, quality control, labeling, supply continuity, and radiopharmacy compliance |
CERETEC’s commercial performance depends on the ability of radiopharmacies and hospitals to obtain both the kit and a reliable Tc-99m supply. Tc-99m is generated from molybdenum-99 and technetium generators, so supply interruptions can affect use even when the CERETEC kit itself remains available.
What patents protect CERETEC?
The original patent estate for exametazime and its principal clinical uses is no longer a meaningful barrier to entry. CERETEC was first approved in the early 1990s, placing the original patent term and regulatory exclusivities well behind the product.
Patent protection overview
| Protection category |
Current commercial position |
| Exametazime composition patents |
Expired |
| Original cerebral-perfusion use patents |
Expired |
| Leukocyte-labeling use patents |
Expired or commercially immaterial |
| Kit formulation patents |
Any original rights are expired |
| Manufacturing-process patents |
Potentially relevant only if later-filed and jurisdiction-specific |
| Radiolabeling workflow know-how |
May remain confidential but is not equivalent to patent exclusivity |
| Orange Book patent blocking |
No known active patent barrier comparable to a recently launched branded drug |
Radiopharmaceutical competitors can enter through alternative kits, alternative labeling agents, hospital-compounded preparations where permitted, or different imaging technologies. Commercial barriers are more likely to involve regulatory compliance, validated manufacturing, sterile production, distribution, and customer familiarity than enforceable patent rights.
What is the Orange Book status of CERETEC?
CERETEC is an approved prescription diagnostic radiopharmaceutical, but its Orange Book position does not resemble that of a branded small-molecule drug with active listed patents and Paragraph IV litigation.
The relevant regulatory conclusions are:
- CERETEC’s original market exclusivity has expired.
- No active patent estate is known to block generic or alternative kit development.
- A potential entrant would need to address FDA requirements for pharmaceutical equivalence, radiochemical performance, sterility, stability, labeling, and kit preparation.
- A patent certification dispute is less likely than a standard abbreviated approval or alternative NDA strategy, depending on the product and regulatory pathway.
For radiopharmaceutical kits, the commercial approval path can be shaped by product-specific FDA requirements. A competitor cannot rely solely on chemical similarity; it must demonstrate that its kit performs consistently when labeled with Tc-99m and used in the approved clinical workflow.
Are there Paragraph IV challenges to CERETEC?
No major publicly documented Paragraph IV litigation has established a current market threat to CERETEC. The product’s age and limited patent protection reduce the incentive for a conventional Paragraph IV campaign.
Potential entrants would more likely pursue:
- An abbreviated application if the FDA pathway supports it.
- A full or supplemental NDA for a comparable radiopharmaceutical kit.
- A different Tc-99m labeling agent.
- A hospital or radiopharmacy preparation pathway permitted under applicable law.
- A product supplied outside the United States under national radiopharmaceutical rules.
The absence of prominent Paragraph IV litigation does not eliminate competitive pressure. It indicates that competition is more likely to arise through regulatory substitution and operational execution than through patent invalidity litigation.
What formulations are protected by CERETEC?
CERETEC is supplied as a sterile kit designed for reconstitution and radiolabeling. The kit contains exametazime and excipients needed to produce the radiolabeled preparation after the addition of Tc-99m pertechnetate.
The commercial value of the formulation lies in:
- Adequate radiochemical labeling efficiency.
- Stability during the permitted preparation period.
- Sterility and pyrogen control.
- Compatibility with radiopharmacy workflows.
- Reproducible leukocyte labeling.
- Acceptable biodistribution and image quality.
These attributes may be protected by manufacturing know-how, quality systems, supplier controls, and regulatory documentation. They do not necessarily create long-term patent exclusivity. A competitor could reproduce the active chemical concept while still facing meaningful development costs to establish product quality and operating reliability.
How strong is the CERETEC patent estate?
CERETEC has weak patent exclusivity but moderate practical market defensibility.
| Factor |
Assessment |
Business implication |
| Composition-of-matter protection |
Weak or expired |
Low litigation barrier |
| Use patents |
Weak or expired |
Limited protection for core indications |
| Formulation patents |
Limited value |
Competitors can pursue comparable kits |
| Manufacturing know-how |
Moderate |
Supports quality and consistency |
| Regulatory familiarity |
Moderate to strong |
Hospitals prefer known workflows |
| Distribution network |
Moderate |
Local supply reliability matters |
| Tc-99m availability |
External constraint |
Generator and isotope supply can affect sales |
| Clinical switching costs |
Moderate |
Radiopharmacy validation and staff training slow substitution |
| Substitution by PET or other imaging |
Moderate |
Technology shifts can reduce demand in selected indications |
The product’s moat is operational rather than patent-based. A new entrant must produce a reliable kit, maintain sterile manufacturing, secure isotope-compatible logistics, obtain regulatory approval, and persuade nuclear-medicine departments to change validated procedures.
What patent litigation affects CERETEC?
No major ongoing patent litigation involving CERETEC is a central market event. The historical intellectual-property disputes associated with exametazime are less commercially relevant than current supply, manufacturing, and regulatory issues.
Litigation risk could arise from:
- A later-filed manufacturing or formulation patent.
- Contract disputes involving distribution or licensing.
- Regulatory exclusivity disputes involving a follow-on radiopharmaceutical.
- Trade-secret claims involving kit production or labeling procedures.
- Product-liability claims related to preparation or administration.
These risks are distinct from the patent litigation profile of newer drugs. CERETEC is unlikely to generate high-value patent settlements comparable to branded oncology, immunology, or metabolic products.
Which companies compete with CERETEC?
Competition occurs at three levels: direct Tc-99m exametazime alternatives, other leukocyte-labeling products, and competing imaging modalities.
Direct and near-direct competition
| Competitive category |
Examples |
Competitive effect |
| Tc-99m exametazime products |
CERETEC and region-specific alternatives |
Direct kit substitution |
| Tc-99m leukocyte-labeling agents |
Alternative labeling chemistry |
Competes in infection imaging |
| In-111-labeled leukocytes |
Indium-111 leukocyte imaging |
Alternative radionuclide workflow |
| Tc-99m sulfur colloid |
Bone marrow and inflammatory imaging applications |
Partial substitution |
| FDG PET/CT |
Infection, inflammation, oncology, and brain imaging |
Strong modality competition |
| Amyloid PET |
Alzheimer’s disease evaluation |
Substitutes in selected cognitive-workup pathways |
| Perfusion SPECT agents |
Tc-99m sestamibi, tetrofosmin, and related agents |
Compete for SPECT capacity, though not always indication-for-indication |
The main commercial competitors are not necessarily companies selling an identical HMPAO kit. They include manufacturers of other radiopharmaceuticals, PET agents, imaging equipment, isotope generators, and radiopharmacy services.
What is the CERETEC market size and revenue exposure?
Public company disclosures generally do not provide standalone CERETEC revenue. Sales are typically reported within broader nuclear-medicine or pharmaceutical portfolios. Product-specific revenue estimates therefore require channel data, procurement records, or management disclosures.
The addressable market is driven by:
- Number of nuclear-medicine departments.
- SPECT camera utilization.
- Tc-99m generator availability.
- Infection-imaging volumes.
- Neurology and dementia imaging practices.
- Reimbursement for leukocyte scintigraphy and cerebral perfusion SPECT.
- Radiopharmacy labor and preparation capacity.
- Competition from PET and MRI.
CERETEC is a niche product relative to the broader radiopharmaceutical market. Its revenue exposure is likely concentrated in hospital and radiopharmacy accounts rather than retail prescriptions. The product can maintain clinical relevance despite modest absolute revenue because it supports specialized diagnostic workflows that are difficult to replace immediately.
What is the CERETEC market forecast through 2030?
The most defensible forecast is a mature-market scenario model rather than a precise product-revenue estimate.
| Market driver |
2025-2030 direction |
Effect on CERETEC |
| Growth in nuclear-medicine procedures |
Low to moderate growth |
Positive |
| Expansion of SPECT in emerging markets |
Moderate positive |
Positive |
| Tc-99m supply reliability |
Variable |
Positive or negative by region |
| PET substitution |
Moderate negative |
Negative in selected indications |
| Aging population and dementia workups |
Positive |
Supports cerebral perfusion use |
| Infection and inflammation imaging |
Stable to positive |
Supports leukocyte-labeling use |
| Radiopharmacy labor costs |
Rising |
Negative |
| Generic or alternative kit entry |
Possible |
Pricing pressure |
| Product shortages |
Episodic |
Can reduce realized sales |
| Patent expiry |
Already reflected |
Limited incremental impact |
Base-case projection
A reasonable base case is:
- North America and Western Europe: flat to low-single-digit annual decline.
- Asia-Pacific and selected emerging markets: mid-single-digit annual growth from a smaller base.
- Global CERETEC-related demand: approximately flat to low-single-digit annual growth through 2030.
- Average price pressure: low to mid-single digits where alternative kits become available.
- Volume growth: positive in markets expanding SPECT capacity.
- Net revenue growth: below procedure-volume growth because of pricing and substitution.
The highest-growth opportunity is not a new patented indication. It is geographic expansion into hospitals with established SPECT infrastructure but limited access to PET. The principal downside is substitution by FDG PET/CT and other advanced imaging methods, especially where reimbursement and isotope supply favor PET.
What generic launch risks exist for CERETEC?
Generic or follow-on entry is technically feasible but operationally complex.
Key entry barriers
- Radiochemical performance: The entrant must achieve consistent Tc-99m labeling and acceptable biodistribution.
- Sterile manufacturing: Production requires validated aseptic processes and quality systems.
- Short operational windows: Radiopharmacies must coordinate kit preparation with isotope availability and patient scheduling.
- Clinical workflow validation: Hospitals may require internal validation before switching products.
- Distribution: The product must reach radiopharmacies quickly and reliably.
- Regulatory documentation: Stability, impurity, radiochemical purity, sterility, and labeling data are central.
- Limited market size: The opportunity may not justify large development or sales investments.
- Alternative modalities: A lower-priced kit still competes with PET, MRI, and other diagnostic procedures.
A successful entrant would likely compete on supply reliability, price, preparation simplicity, technical support, and geographic coverage rather than on patent differentiation.
What licensing deals affect CERETEC?
No major current licensing transaction is a primary valuation driver for CERETEC. The product is a mature commercial radiopharmaceutical, and any relevant arrangements are more likely to involve:
- Regional commercialization rights.
- Contract manufacturing.
- Radiopharmacy distribution.
- Isotope supply agreements.
- Portfolio transfers involving nuclear-medicine products.
- Local regulatory sponsorship.
Licensing economics are constrained by the product’s niche size and mature pricing. A transaction would be more likely to occur as part of a broader radiopharmaceutical portfolio than as a standalone CERETEC deal.
How does CERETEC compare with FDG PET and other infection-imaging products?
| Dimension |
CERETEC |
FDG PET/CT |
In-111 leukocytes |
| Core use |
Leukocyte infection imaging and cerebral perfusion |
Oncology, infection, inflammation, brain metabolism |
Infection and inflammation |
| Isotope |
Tc-99m |
F-18 |
In-111 |
| Infrastructure |
SPECT and radiopharmacy |
PET/CT and cyclotron or distribution network |
Nuclear-medicine facility |
| Workflow |
Cell labeling and reinjection |
Direct tracer administration |
Cell labeling and reinjection |
| Geographic availability |
Broad where Tc-99m is available |
Strong but uneven |
More limited |
| Operational complexity |
High |
Moderate |
High |
| Patent protection |
Mature and weak |
Product-specific, often mixed |
Mature |
| Main advantage |
Established workflow and Tc-99m access |
Higher sensitivity and whole-body capability in many settings |
Established alternative for selected infections |
| Main risk |
PET substitution and preparation burden |
Cost and access |
Longer imaging workflow and isotope constraints |
CERETEC remains most competitive where Tc-99m SPECT is readily available and PET access is limited or economically unfavorable.
Key Takeaways
- CERETEC is a mature Tc-99m exametazime radiopharmaceutical kit, not an active new-drug development program.
- Its main uses are cerebral perfusion imaging and in vitro leukocyte labeling for infection or inflammation.
- No major current clinical-trial program, Paragraph IV campaign, or patent litigation materially changes its market position.
- Original composition, use, and formulation protection is expired or commercially weak.
- The principal barriers to competition are sterile manufacturing, radiochemical consistency, regulatory approval, isotope logistics, and hospital workflow adoption.
- Developed-market demand is likely flat to modestly declining through 2030.
- Emerging-market SPECT expansion can support low to moderate global growth.
- FDG PET/CT is the largest technology-level competitive risk.
- Standalone CERETEC revenue is generally not disclosed, limiting precise company-level revenue attribution.
- The product’s commercial value is operational and clinical, not patent-based.
Frequently Asked Questions
Is CERETEC still FDA approved?
Yes. CERETEC is an FDA-approved diagnostic radiopharmaceutical kit associated with NDA 019793. Its label covers cerebral perfusion imaging and in vitro leukocyte labeling.
Is CERETEC a biologic or eligible for biosimilar competition?
No. CERETEC is a small-molecule radiopharmaceutical kit containing exametazime for labeling with Tc-99m. Biosimilar law does not apply.
Can a generic company copy CERETEC?
A competitor can potentially develop a comparable exametazime kit, but it must establish pharmaceutical quality, radiochemical labeling performance, sterility, stability, and regulatory compliance. Patent expiry does not remove these technical and operational requirements.
Does CERETEC diagnose Alzheimer’s disease?
CERETEC can provide cerebral perfusion information used in selected neurologic evaluations, including dementia workups. It is not an Alzheimer’s disease-specific diagnostic and does not replace molecular amyloid or tau imaging.
What is the main long-term threat to CERETEC sales?
The main threat is modality substitution, particularly FDG PET/CT and other advanced imaging approaches, combined with radiopharmacy labor requirements and intermittent Tc-99m supply constraints.
References
-
U.S. Food and Drug Administration. (2024). CERETEC (technetium Tc 99m exametazime kit) prescribing information. FDA-approved labeling.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: CERETEC, NDA 019793. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. National Library of Medicine. (2024). ClinicalTrials.gov database. https://clinicaltrials.gov/
-
International Atomic Energy Agency. (2023). Technetium-99m radiopharmaceuticals and nuclear medicine practice. IAEA.
-
Society of Nuclear Medicine and Molecular Imaging. (2018). Appropriate use criteria for infection and inflammation imaging. Journal of Nuclear Medicine.
